Get the Stockscreener App
24.91
0.52%
0.13
Elanco Animal Health Inc stock is traded at $24.91, with a volume of 4.08M.
It is up +0.52% in the last 24 hours and up +3.96% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
See More
Previous Close:
$24.78
Open:
$25.12
24h Volume:
4.08M
Relative Volume:
0.71
Market Cap:
$12.44B
Revenue:
$4.89B
Net Income/Loss:
$-242.00M
P/E Ratio:
-50.94
EPS:
-0.489
Net Cash Flow:
$315.00M
1W Performance:
-3.56%
1M Performance:
+3.96%
6M Performance:
+2.09%
1Y Performance:
+69.57%
1-Day Range:
$24.60
$25.27
1-Week Range:
$24.59
$26.21
52-Week Range:
$13.39
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
24.91 | 12.44B | 4.89B | -242.00M | 315.00M | -0.489 |
TAK
Takeda Pharmaceutical Co Adr
|
17.24 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.78 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.81 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.35 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
528.47 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Buy |
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
ELAN4667244 Bond Profile — Key Metrics - TradingView
Elanco Animal Health Incorporated $ELAN Shares Purchased by Sei Investments Co. - MarketBeat
Elanco Animal Health Incorporated (ELAN) stock price, news, quote and history - Yahoo Finance UK
Rising parasite threats put pets and livestock at risk as tick levels surge nationwide - KOKH
Elanco Animal Health Incorporated (ELAN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Credelio Quattro™ Kills Ticks(1) Faster(2) Than Simparica Trio® and NexGard® Plus - CSRwire
Elanco Animal Health Price Target Raised to $26.00/Share From $23.00 by Morgan Stanley - Moomoo
ELAN Maintained by Morgan Stanley -- Price Target Raised to $26. - GuruFocus
Morgan Stanley Issues Positive Forecast for Elanco Animal Health (NYSE:ELAN) Stock Price - MarketBeat
Are You Looking for a Top Momentum Pick? Why Elanco Animal Health Incorporated (ELAN) is a Great Choice - Yahoo Finance
Elanco Animal Health Incorporated Stock 12‑Month Price Target Raised to $30.23, Implies 19% Upside - TradingView
Elanco’s Credelio Quattro shows faster tick kill in study By Investing.com - Investing.com Canada
Elanco's Credelio Quattro Maintains 8-Hour Tick Kill Through Day 28 - Stock Titan
Elanco Animal Health Incorporated $ELAN Shares Sold by Bank of New York Mellon Corp - MarketBeat
Dimensional Fund Advisors LP Has $586.92 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
LLY4841184 Bond Profile — Key Metrics - TradingView
Jennison Associates LLC Purchases 494,216 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Principal Financial Group Inc. Grows Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
472,814 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Dorsey Wright & Associates - MarketBeat
Allspring Global Investments Holdings LLC Acquires New Shares in Elanco Animal Health Incorporated $ELAN - MarketBeat
KIN stock trades quietly as Kindred Biosciences acquisition leaves legacy metrics in focus - ad-hoc-news.de
Geneos Wealth Management Inc. Purchases 196,884 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Fifth Third Bancorp Grows Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Ends Apollo Government Relations Lobbying Deal - Legis1
Will Elanco Animal Health (ELAN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
ECO Animal Health delivers stronger than expected results as vaccine strategy gains momentum (EAH) - Yahoo Finance UK
Elanco Animal Health (NYSE: ELAN) awards CEO new deferred stock units - Stock Titan
Elanco Animal Health (NYSE: ELAN) awards CFO new deferred stock units - Stock Titan
Elanco Animal Health (NYSE: ELAN) awards deferred stock units to company officer - Stock Titan
Dimensional Fund Advisors reports 5.1% Elanco Animal Health (ELAN) stake - Stock Titan
Elanco Animal Health Incorporated (NYSE:ELAN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Elanco Helped Puppies Fight Parvo - CSRwire
Form 4 Elanco Animal Health For: 9 July By Investing.com - Investing.com Nigeria
Elanco (NYSE: ELAN) CFO uses 15,336 shares to cover tax liability - Stock Titan
Elanco Confirms Date and Conference Call for Second Quarter 2026 Financial Results Announcement - GuruFocus
Elanco sets Aug. 5 call for second-quarter 2026 results - Stock Titan
Elanco to Launch Elanco Ventures with $25 Million Multi-Year Commitment to Accelerate Innovation in Animal Health - AOL.com
Integrated Advisors Network LLC Purchases New Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Strs Ohio Grows Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
SG Americas Securities LLC Reduces Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elanco Animal Health - TMX Newsfile
NYSE: ELAN Lawsuit Alert: Investors who lost money with Elanco A - GuruFocus
Elanco Animal Health Inc (NYSE:ELAN) Technical Breakout Setup Scores 10/10 Technical Rating and 9/10 Setup Quality - ChartMill
Form 4 Elanco Animal Health For: 2 July By Investing.com - Investing.com Nigeria
Elanco (ELAN) executive awarded 25,620 stock options at $24.09 strike price - Stock Titan
Elanco (ELAN) director converts cash fees into 584 deferred stock units - Stock Titan
Form 4 Elanco Animal Health For: 30 June By Investing.com - Investing.com Canada
Elanco (NYSE: ELAN) executive receives new deferred stock unit award - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons receives 115 deferred stock units grant - Stock Titan
Elanco (NYSE: ELAN) CFO gets new deferred stock unit award - Stock Titan
Elanco Commits To Supporting US In Fight Against Screwworm - InkFreeNews.com
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):